| Description |
Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats[1].
|
| Related Catalog |
|
| Target |
IC50: GLP-1 receptor[1]
|
| In Vivo |
Exendin (5-39) (intracerebroventricular injection; 0.3 μg; once daily; 1-week) increases GLT-1 protein levels in the hippocampus of male Wistar rats. Additionally, hippocampal slices are prepared from Ex-treated or vehicle rats,Exendin (5-39) decreases fEPSP decay time and increases the input-output relation and decreased the paired-pulse ratio in the dentate gyrus (DG). Furthermore, Ex inhibits long-term depression but not long-term potentiation in the DG[1]. Animal Model: Wistar rats (3 weeks old and 18 days pregnant)[1] Dosage: 0.3 μg Administration: Intracerebroventricular injection; 0.3 μg; once daily; 1-week Result: Inhibited GLT-1 protein levels and inhibited long-term depression in rats.
|
| References |
[1]. Kazuma Kobayashi, et al. Exendin (5-39), an antagonist of GLP-1 receptor, modulates synaptic transmission via glutamate uptake in the dentate gyrus. Brain Res. 2013 Apr 10;1505:1-10.
|
